Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of tofacitinib in moderate to severe chronic plaque psoriasis
2010-020003-73Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in psoriasis (3 arms), sponsored by Pfizer. Primary endpoint: Primary efficacy endpoint. Started Dec 2010; status: completed.
02
Drugs
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2010-020003-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020003-73.